Silo Pharma's SPU-21 Treatment For Autoimmune Disease Awarded U.S. Patent 16/825,371 Titled "Peptide-Targeted Liposomal Delivery For Treatment, Diagnosis, And Imaging Of Diseases And Disorders"
Portfolio Pulse from Happy Mohamed
Silo Pharma has been awarded U.S. Patent 16/825,371 for its SPU-21 peptide-guided anti-arthritis drug, which selectively targets inflamed synovial tissue. The patent strengthens protection for the ongoing development of SPU-21 as a therapeutic agent for rheumatoid arthritis.
June 21, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silo Pharma's SPU-21 anti-arthritis drug has been awarded a U.S. patent, strengthening protection for its ongoing development as a therapeutic agent for rheumatoid arthritis.
The U.S. patent award for Silo Pharma's SPU-21 drug strengthens the company's intellectual property protection and supports its ongoing development as a therapeutic agent for rheumatoid arthritis. This news is likely to have a positive impact on the company's stock price in the short term, as it demonstrates progress in the development of their product and potential future revenue from the rheumatoid arthritis market, which is expected to generate $63 billion by 2027.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100